PT  - JOURNAL ARTICLE
AU  - W. Bou-Assaly
AU  - S. Mukherji
TI  - Cetuximab (Erbitux)
AID  - 10.3174/ajnr.A2054
DP  - 2010 Apr 01
TA  - American Journal of Neuroradiology
PG  - 626--627
VI  - 31
IP  - 4
4099  - http://www.ajnr.org/content/31/4/626.short
4100  - http://www.ajnr.org/content/31/4/626.full
SO  - Am. J. Neuroradiol.2010 Apr 01; 31
AB  - SUMMARY: Cetuximab, a recombinant chimeric monoclonal antibody, has been successfully used in the treatment of the head and neck and colorectal cancers. We present a review of its mechanism of action, indications, side effects and economic issues, accompanied by a clinical example from our institution. EGFRepidermal growth factor receptorFDAUS Food and Drug AdministrationHERhuman epidermal growth factor receptorSCCsquamous cell carcinomaSCCHNSCC of the head and neck